{
  "id": "fd3d55c6b0f26ce3",
  "title": "Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting",
  "description": "Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meet",
  "content": "ST. LOUIS, Mo., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological malig\u2026 [+4514 chars]",
  "source": "GlobeNewswire",
  "source_url": "https://www.globenewswire.com/news-release/2025/12/05/3200578/0/en/Wugen-to-Present-Correlative-Data-and-Long-Term-Follow-Up-Updates-for-Off-the-Shelf-Allogeneic-CD7-Targeted-CAR-T-Cell-therapy-at-the-2025-ASH-Annual-Meeting.html",
  "published_at": "2025-12-05T12:00:00Z",
  "fetched_at": "2025-12-06T18:33:06.472112+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "search:gene therapy CRISPR trial"
  ],
  "location": null,
  "raw_data": {
    "source": {
      "id": null,
      "name": "GlobeNewswire"
    },
    "author": "Wugen",
    "title": "Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting",
    "description": "Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meet",
    "url": "https://www.globenewswire.com/news-release/2025/12/05/3200578/0/en/Wugen-to-Present-Correlative-Data-and-Long-Term-Follow-Up-Updates-for-Off-the-Shelf-Allogeneic-CD7-Targeted-CAR-T-Cell-therapy-at-the-2025-ASH-Annual-Meeting.html",
    "urlToImage": "https://ml.globenewswire.com/Resource/Download/45bc8c22-6919-4005-87d6-1873ad0cc3b6",
    "publishedAt": "2025-12-05T12:00:00Z",
    "content": "ST. LOUIS, Mo., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological malig\u2026 [+4514 chars]"
  }
}